Ketamine for depression: all studies (page 51)

Antidepressant effects of esketamine are associated with functional connectivity in the hippocampal subregion: A resting state magnetic resonance study.

Neuroscience July 8, 2025 Xiang Liu, Yumeng Liu, Jun Tu et al. 2 citations

We aimed to investigate the relationship between changes in resting-state functional connectivity in a subregion of the hippocampus and the antidepressant effects of esketamine as well as to identify potential neuroimaging markers of the treatment outcomes. Twenty-nine patients with major depressive disorder (MDD) received six intravenous infusions of esketamine. All patients completed the...

DOI: 10.1016/j.neuroscience.2025.07.016 Full text Esketamine Major depressive disorder Mdd Functional connection +14

S-ketamine ameliorates post-stroke depression in mice via attenuation of neuroinflammation, synaptic restoration, and BDNF pathway activation.

Biochemical and Biophysical Research Communications July 8, 2025 Jiaxin Tian, Yanhong Xie, Sen Ye et al. 6 citations

The available therapeutic options for post-stroke depression patients are limited. Although SSRIs are the most commonly prescribed antidepressants, their slow onset of action and the higher risk of adverse effects or contraindications have led to an urgent need to develop fast-acting and highly specific antidepressants tailored to the needs of PSD patients. Therefore, ketamine has drawn...

DOI: 10.1016/j.bbrc.2025.151965 Full text S-ketamine Neuroinflammation Post-stroke depression psd Synaptic function +5

Mu Opioid Receptor Activation is Required for NMDA Receptor Antagonist Effects on Stress-induced Maladaptive Behavior.

Biological Psychiatry July 7, 2025 Cory B Langreck, Briana K Chen, Victor M Luna et al. 9 citations

Contradictory evidence has emerged regarding the role of the mu opioid receptor (MOR) in the antidepressant actions of (R,S)-ketamine. Here, we used the long-acting MOR-selective antagonist methocinnamox (MCAM) to determine the contribution of MOR to the actions of (R,S)-ketamine and the more selective N-methyl-D-aspartate receptor (NMDAR) antagonist fluoroethylnormemantine (FENM) against...

DOI: 10.1016/j.biopsych.2025.07.004 Full text Ketamine Fear Nmdar antagonists nmdar Similar compounds +10

Esketamine disinhibits brain networks in depression: Evidence from oscillatory and aperiodic activity.

Progress in Neuro-Psychopharmacology and Biological Psychiatry July 5, 2025 Verina Guirguis, Sanvi Korsapathy, Francesca Pupillo et al. 6 citations

Nasal Esketamine is a rapid-acting intervention for depression, hypothesized to exert its effects through cortical disinhibition. However, the spatio-temporal dynamics of brain network activity and their relationship to the subjective drug experience following Esketamine administration remain elusive. This observational study aims to delineate brain network-level effects of Esketamine by...

DOI: 10.1016/j.pnpbp.2025.111438 Full text Major depressive disorder Aperiodic exponent Brain oscillations Esketamine treatment +9

Plasma esketamine and noresketamine levels and antidepressant response with oral esketamine treatment.

European Journal of Pharmacology July 5, 2025 Jolien K E Veraart, Sanne Y Smith-Apeldoorn, Jeanine Kamphuis et al. 2 citations

Oral esketamine has relatively low and variable bioavailability, which may complicate broader use as an antidepressant. This study aimed to investigate associations between different pharmacokinetic outcomes and change in depressive symptoms following oral esketamine administration in patients with treatment-resistant depression. Understanding such associations may inform dosing and...

DOI: 10.1016/j.ejphar.2025.177470 Full text Mdd Spravato Clinical depression Esketamine ketamine +5

Esketamine Monotherapy in Adults With Treatment-Resistant Depression: A Randomized Clinical Trial.

JAMA Psychiatry July 2, 2025 Adam Janik, Xin Qiu, Rosanne Lane et al. 40 citations

Esketamine nasal spray, administered in conjunction with an oral antidepressant, is approved for treatment-resistant depression (TRD). However, the efficacy of esketamine nasal spray administered as monotherapy for patients with TRD has not yet been evaluated. To assess the efficacy and safety of esketamine monotherapy compared to placebo in reducing depressive symptoms in patients with TRD....

DOI: 10.1001/jamapsychiatry.2025.1317 Full text Esketamine nasal spray Treatment-resistant depression Depression treatment Antidepressant therapy +35

Understanding the Experience of Ketamine-Assisted Therapy and the Importance of Context.

Journal of Psychoactive Drugs July 2, 2025 Grace Stockwell, Nicholas Hoeh, Francesca Fogarty et al. 2 citations

Ketamine-assisted therapy (KAT) is a novel modality that shows promise as a treatment for depression. The current study sought to add to the scarce research in the area and inform future applications of KAT for patients with treatment-resistant depression. The study used in-depth qualitative interviews (N = 12) to explore participants' perceptions of KAT, including working with therapists, the...

DOI: 10.1080/02791072.2025.2527299 Full text Ketamine-assisted therapy Depression treatment Therapeutic environment

Symptom Reduction and Deprescribing in a Patient With Treatment-Resistant Depression Using Sublingual Ketamine Troches: A Case Report.

Cureus July 1, 2025 Elizabeth Francis

Treatment-resistant depression (TRD) remains a significant clinical challenge, often accompanied by polypharmacy and comorbid anxiety or trauma-related disorders. This report describes a 37-year-old male with longstanding major depressive disorder (MDD), post-traumatic stress disorder (PTSD), and social anxiety disorder who demonstrated limited response to traditional pharmacologic strategies,...

DOI: 10.7759/cureus.87343 Full text Psychedelic-assisted therapy Complex-PTSD Ketamine infusion Low dose ketamine

A Narrative Review: The Role that Ketamine May Play in the Treatment of Depression and the Underlying Mechanisms of Its Effect

BILT Student Research Journal 2025 - Issue 6 July 1, 2025 Sophie Höfels 1 citation

The novel antidepressant ketamine has been shown to achieve what most classic antidepressants, such as Selective Serotonin Reuptake Inhibitors, have not been able to. A rapid onset of symptomatic improvement across multiple domains; mood, anhedonia, and suicidal ideation. The exact neuropsychopharmacological mechanisms of this unique phenomenon are still unknown, although many theories are...

DOI: 10.70969/20251001 Full text Ketamine Depression economics Narrative review Psychotherapist +3

Intranasal esketamine significantly alleviates depression severity and suicidal ideations in electroconvulsive therapy (ECT) non-responders.

European Archives of Psychiatry and Clinical Neuroscience July 1, 2025 Erhan Kavakbasi, Kevin Rosemann, Mert Yilmaz et al. 2 citations

Intranasal esketamine (ESK) is a novel therapy option in patients with treatment-resistant depression (TRD). Patients with a history of electroconvulsive therapy (ECT) non-response (ECT+) in the current episode have usually been excluded from previous studies. Data on the effectiveness of ESK in ECT non-responders are sparse. In this retrospective study, we investigated the effectiveness of...

DOI: 10.1007/s00406-025-02041-9 Full text Esketamine Major depressive disorder Electroconvulsive therapy Novel antidepressants +1